Skip to main content
  • twitter
  • facebook
  • linkedin
INEX listed in Financial Times ranking of 500 of Asia-Pacific’s high-growth companies
  • Call us +65 6773 0698
Hit enter to search or ESC to close
Close Search
INEX Innovate
Menu
  • The Company
    • Company
    • Team
  • Products
    • CORO®
    • OvaCis®
    • epiDx®
    • epiHERA™
    • XENA®
    • LEXI®
  • Laboratory
  • Partnerships
  • Investor Relations
  • Publications
  • News
  • Contact

Filter

Announcements
AnnouncementsConventions

INEX Innovate at MEDICA 2022 Dusseldorf to showcase the OvaCis® Rapid Test Kit – the world’s first intraoperative rapid test to effectively discriminate benign from malignant ovarian cysts.

November 8, 2022
Announcements

INEX Innovate is thrilled to share that our Chief Executive, Kane Black, have been selected as Ernst & Young EY Singapore Entrepreneur Of The Year – Biotechnology

October 18, 2022
AnnouncementsConventions

iGene Laboratory is proud to be 1 of the sponsors for NUS, Department of Obetetrics and Gynecology, Centennial Research and Education Meeting

October 9, 2022
Announcements

INEX Innovate being awarded with SME100 Awards, organized by SME Magazine naming the fastest moving businesses of the SME sector

September 22, 2022
AnnouncementsConventions

iGene Laboratory presents at this year’s Medical Genetics Conference Kuala Lumpur 2022 – with our very own Dr Sherry Ho as one of the guest speakers

September 13, 2022
Announcements

Sponsored by INEX Innovate, the evening saw three up and coming Clinician Scientists receive the INEX-OSCAR Award

August 27, 2022
AS FEATURED ON

Let's shake the diagnostics status quo and put scientific discoveries into clinical practice

Partnerships are vital for continued medical advancements. We constantly seek collaborators to:

  • Support existing research and clinical programmes
  • Diversify our portfolio with new technology in women’s and reproductive health
  • Accelerate the development of innovative diagnostics tools

Let's work together to improve the lives of women around the world.

CONTACT US
Head Office

6 Raffles Quay
#14-04/05
Singapore 048580

Laboratory

1 Science Park Road
#04-10 The Capricorn
Singapore 117528

Connect
Call +65 6773 0698
Fax +65 6873 0240
Terms of Use
Privacy Policy

Please note that the contents of this website are for corporate and non-commercial information purposes only and are provided on the understanding that no surgical or medical advice or recommendation is being rendered. Please refer to our website Terms of Use. The content of this site may not be construed as advertisements for any product or service that INEX or any of its subsidiary companies offers.

© 2023 INEX INNOVATE PRIVATE LIMITED. ALL RIGHTS RESERVED. 0009-0302-00.

Close Menu
INEX listed in Financial Times ranking of 500 of Asia-Pacific’s high-growth companies
  • The Company
    • Company
    • Team
  • Products
    • CORO®
    • OvaCis®
    • epiDx®
    • epiHERA™
    • XENA®
    • LEXI®
  • Laboratory
  • Partnerships
  • Investor Relations
  • Publications
  • News
  • Contact
  • Call us +65 6773 0698
  • twitter
  • facebook
  • linkedin
About the Technology

A simple sample collection using the common HPV swab is taken and the DNA is extracted. The extracted DNA undergoes bisulfite conversion before an accurate method of screening through real-time PCR analyses. The bisulfite conversion functions by converting unmethylated Cytosine nucleotides to Uracil, which is then converted to Thymine by PCR. Conversely, the methylation mark protects the methylated Cytosine nucleotides from being converted to Uracil.